Clinical and Molecular Investigations of the DF3 Breast Cancer-Associated Antigen

  • Daniel F. Hayes
  • Miyako Abe
  • Javed Siddiqui
  • Carlo Tondini
  • Donald W. Kufe


The murine MAb DF3 is an IgG1 which was generated against a membrane-enriched cell extract prepared from a human breast carcinoma metastatic to liver (1). Immunoperoxidase studies have demonstrated that MAb DF3 clearly distinguishes malignant and benign breast lesions. Whereas MAb DF3 produces a cytosolic staining pattern in 78% of breast carcinomas, such a pattern is observed in less than 10% of fibrocystic lesions or fibroadenomas (1). In contrast, reactivity of benign breast lesions with MAb DF3 is primarily on the apical borders of the ductules. MAb DF3 also reacts with a variety of non-mammary adenocarcinomas, but, of note, not with colon carcinomas (1). MAb DF3 does not react with tumors of mesenchymal origin. MAb DF3 also reacts with the apical surface of normal breast ductal epithelium, as well as the apical secretory surfaces of several other normal epithelial tissues such as liver, lung, kidney (distal collecting tubules), bladder, testis, uterus, ovary, and sebaceous and sweat glands (2). MAb DF3 does not react with normal adult spleen, colon, bone marrow, heart, stomach, duodenum, skin, or adrenal cortex (2).


Metastatic Breast Cancer Sodium Butyrate Benign Breast Lesion Partial cDNA Clone High Molecular Weight Glycoprotein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. Kufe, G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler, and J. Schlom: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3, 223–232, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    D. Hayes, E. Friedman, D. Kufe: Radioimmunoscintigraphy of human carcinoma: Characterization of monoclonal antibodies; in Antibodies in Radiodiagnosis and Therapy; Zalutsky, MR (ed), CRC Press, (in press).Google Scholar
  3. 3.
    H. Sekine, T. Ohno, and D. Kufe: Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J. Immunol. 135:3610–3615, 1985.Google Scholar
  4. 4.
    M. Abe, D. Kufe: Effects of maturational agents on expression and secretion of two partially characterized high molecular weight milk-related glycoproteins in MCF-7 breast carcinoma cells. J. Cell. Phys. 126:126–132, 1986.CrossRefGoogle Scholar
  5. 5.
    S. Hull, A. Bright, M. Abe, D. Kufe, and L. Carraway: Oligosaccharides of the DF3 antigen of the BT-20 human breast carcinoma cell line. J. Cell. Biochem. Supp. 12E:130–133, 1988Google Scholar
  6. 6.
    M. Abe, and D. Kufe: Identification of a family of high molecular weight tumor-associated glycoproteins. J. Immunol. 139:257–261, 1987.PubMedGoogle Scholar
  7. 7.
    J. Lundy, A. Thor, R. Maenza, J. Schlom, F. Forouhar, M. Testa and D. Kufe: Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res. Treat. 5:269–276, 1985.PubMedCrossRefGoogle Scholar
  8. 8.
    M. Abe, D. Kufe: Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res. 44:4574–4577, 1984.PubMedGoogle Scholar
  9. 9.
    M. Abe, D. Kufe: Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production. Breast Cancer Research and Treatment 4:269–274, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    D. Hayes, T. Ohno, M. Abe., H. Sekine, and D. Kufe: Detection of elevated plasma DF3 antigen levels in breast cancer patients. J. Cl in. Invest. 75:1671–1678, 1985.CrossRefGoogle Scholar
  11. 11.
    J. Hilkens, F. Buijs, J. Hilgers, P. Hageman, J. Calafat, A. Sonnenberg, and M. Van der Valk: Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer 34:197–206, 1984.PubMedCrossRefGoogle Scholar
  12. 12.
    J. Hilkens, V. Kroezen, H. Bonfrer, M. De Jong-Bakker, and P. Bruning: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 46:2582–2587, 1986.PubMedGoogle Scholar
  13. 13.
    D. Hayes, V. Zurawski, and D. Kufe: Comparison of circulating CA 15–3 and carcinoembryonic antigen in patients with breast cancer. J. Clin. Oncol. 4:1542–1550, 1986.PubMedGoogle Scholar
  14. 14.
    C. Tondini, D. Hayes, R. Gelman, I. Henderson, and D. Kufe: Comparison of CA15–3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 48:4107–4112, 1988.PubMedGoogle Scholar
  15. 15.
    D. Hayes, H. Sekine, D. Marcus, C. Alper, and D. Kufe: Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen. Blood 71:436–440, 1988.PubMedGoogle Scholar
  16. 16.
    C. Alper, and D. Nathan: Serum proteins and other genetic markers of t blood; in Hematology of Infancy and Childhood (ed III); Nathan GD , Oski (eds.) WB Saunders, pp 345–360 (1988).Google Scholar
  17. 17.
    J. Siddiqui, M. Abe, D. Hayes, E. Shani, E. Yunis, and D. Kufe: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl. Acad. Sci. USA 85:2320–2323, 1988.PubMedCrossRefGoogle Scholar
  18. 18.
    V. Holers, D. Chaplin, J. Leykam, B. Gruner, V. Kumar, and J. Atkinson: Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc. Natl. Acad. Sci. (USA) 84:2459–2463, 1987.CrossRefGoogle Scholar
  19. 19.
    D. Swallow, B. Griffiths, M. Bramwell, G. Wiseman, J. Burchell: Detection of the urinary PUM polymorphism by the tumourbinding monoclonal antibodies Cal, Ca2, Ca3, HMFG1, and HMFG2. Dis. Markers 4:247, 1986.PubMedGoogle Scholar
  20. 20.
    D. Swallow, S. Gendler, B. Griffiths, G. Corney, J. Taylor-Papadimitriou, and M. Bramwell: The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature (London) 328:82–84, 1987.Google Scholar
  21. 21.
    S. Gendler, J. Burchell, T. Duhig, D. Lamport, R. White, M. Parker, and J. Taylor-Papadimitriou: Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins by human mammary epithelium. Proc. Natl. Acad. Sci. (USA). 84:6060–6064, 1987.CrossRefGoogle Scholar
  22. 22.
    S. Gendler, J. Taylor-Papadimitriou, T. Duhig, J. Rothbard, and J. Burchell: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 263:12820–12823, 1988.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Daniel F. Hayes
    • 1
  • Miyako Abe
    • 1
  • Javed Siddiqui
    • 1
  • Carlo Tondini
    • 1
  • Donald W. Kufe
    • 1
  1. 1.Laboratory of Clinical PharmacologyDana Farber Cancer InstituteBostonUSA

Personalised recommendations